Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.
about
Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studiesAnimal Models and "Omics" Technologies for Identification of Novel Biomarkers and Drug Targets to Prevent Heart FailureBiomarker as a research tool in linking exposure to air particles and respiratory healthPresent and future pharmacotherapeutic agents in heart failure: an evolving paradigmChallenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugsMyocardial fibrosis: biomedical research from bench to bedside.Effects of fish oil supplementation on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials.Nutrition intervention to decrease symptoms in patients with advanced heart failure.Toll-like receptor 9 mediated responses in cardiac fibroblastsLycopene dietary intervention: a pilot study in patients with heart failureAssociation of interleukin 8 and myocardial recovery in patients with ST-elevation myocardial infarction complicated by acute heart failure.Shenfu Injection suppresses inflammation by targeting haptoglobin and pentraxin 3 in rats with chronic ischemic heart failure.Association between red blood cell distribution width and acute pancreatitis.Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction.The impact of extra cardiac comorbidities on pressure volume relations in heart failure and preserved ejection fraction.Effects of obesity on the association between long-term sleep apnea treatment and changes in interleukin-6 levels: the Icelandic Sleep Apnea Cohort.Cardiac migration of endogenous mesenchymal stromal cells in patients with inflammatory cardiomyopathy.Hypoalbuminaemia and incident heart failure in older adults.Melatonin protects against myocardial hypertrophy induced by lipopolysaccharide.Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload.Evaluation of adenosine deaminase (ADA) isoenzymes activity and tumor necrosis factor-α (TNFα) concentration in chronic heart failureInflammation, Endothelial Dysfunction and Increased Left Ventricular Mass in Chronic Kidney Disease (CKD) Patients: A Longitudinal StudyInflammation and cardiac outcomeDeletion of LOX-1 Protects against Heart Failure Induced by Doxorubicin.MicroRNA therapeutics in cardiovascular medicine.Prognostic Utility of Neutrophil-to-Lymphocyte Ratio on Adverse Clinical Outcomes in Patients with Severe Calcific Aortic Stenosis.Myocardial gene expression profiles and cardiodepressant autoantibodies predict response of patients with dilated cardiomyopathy to immunoadsorption therapyIdentifying panaxynol, a natural activator of nuclear factor erythroid-2 related factor 2 (Nrf2) from American ginseng as a suppressor of inflamed macrophage-induced cardiomyocyte hypertrophy.Drug target identification using network analysis: Taking active components in Sini decoction as an example.How can we cure a heart "in flame"? A translational view on inflammation in heart failure.Is CaMKII a link between inflammation and hypertrophy in heart?Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life?IL-33/ST2 pathway and classical cytokines in end-stage heart failure patients submitted to left ventricular assist device support: a paradoxic role for inflammatory mediators?An essential role of Nrf2 in American ginseng-mediated anti-oxidative actions in cardiomyocytes.Molecular Characterization of Pediatric Restrictive Cardiomyopathy from Integrative GenomicsMonocytes in heart failure: relationship to a deteriorating immune overreaction or a desperate attempt for tissue repair?Multiple cytokine biomarkers in heart failure.Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation.Cardiorenal syndrome: diagnosis, treatment, and clinical outcomes.Therapeutic targeting of innate immunity in the failing heart.
P2860
Q26746907-9EE40E24-9B5B-4762-8DC3-E3CC41C54A65Q26799838-0956D8A7-1D16-458F-BABA-4EA867ADC4B4Q27012783-6B9632DC-6C2C-4A54-8AA2-2B034DD8688CQ28077186-92CF0F19-866A-4A6C-853B-DE45252E1C62Q28085736-BD92D4C7-56D3-4D72-A8AE-A451587A587FQ30362840-DDA4481B-F779-4193-BE15-ABF8E1AB1E4DQ31096498-E497129A-CF2B-48F1-B0C0-02F7328CE277Q33572474-FB8C965E-D28F-40A0-B5CB-44EF89C90D45Q34050642-D7B107D9-AF6D-4436-A116-2539A8EE984AQ34207466-6FE2F25C-639E-4F82-BA34-7E2B89A414FBQ34498176-CF66E3F8-045B-464E-91BF-A1DF3A9F79FFQ34620837-8FF2B56A-B207-4CE6-B388-319694D0FEF5Q34639226-3F080D7D-E868-4BBA-9CA7-F5439C72DBF8Q35026270-B7EED1D2-962B-4DC7-BBE8-8B4E35F4D980Q35072339-70C1D9AA-59FE-4879-95F1-C6968C3088A6Q35152108-4B51CC47-62BC-4D16-8280-6043C18D2C4CQ35177936-E3BC0239-D299-4CE7-A713-DE00AFDC9377Q35224984-00207948-0787-495F-B620-EFFF4B5B69DBQ35490630-F904B970-7C5B-43F3-9AFF-4A89457A51B6Q35534909-4456897F-8555-4ED8-8EA2-657F83B28675Q35721547-B0D0E77F-6AB7-4F32-A3F4-FD02DF1FBDBAQ35784920-15CF9C6E-3CA9-4122-9EEF-D8A70C39D1B1Q35835539-93D88D5F-31EE-4D22-AB25-4057C10EB4F7Q36022217-84EFE78B-4BAF-49AB-83CD-5456C269C8C2Q36037919-4C934CB0-BFAA-41F0-8B85-6209B20D6EFCQ36109103-C13356F7-BEB6-48A6-863C-C8C0B34DFFCEQ36647124-55612B44-5645-4027-BAB2-64C28FD983D7Q36736742-6885E09D-F3A5-4C3A-931F-7BC3249AF333Q36814771-A60E15E7-A71E-4072-8FA3-75C00BBB09ADQ37004826-0DA85F85-1199-4B7D-9FCF-2B1BE9F6B151Q37064322-F7C16B87-33E9-4CAB-8FB4-28A089B56C66Q37292234-B14DB0CA-6183-4C15-A559-A1E13127E36CQ37413342-E180DC00-44DE-4CAF-8F15-AA1C343AF70BQ37576766-BF660001-CD62-478C-89D3-0B3A30D6D989Q37591259-F35B73A2-80E1-42B8-93FB-28900D65524FQ37608787-E2D06312-0EC1-4BB9-9E42-5087182B474CQ37705430-23F148ED-A873-4AE6-A2F7-CA6D03912ABFQ37775559-FEA90FA9-F821-4F87-9A0F-4F4A372CBAFDQ37782283-D303ACF2-3BFC-4E3A-8CC3-ED183847312CQ37809215-CB604919-9848-4C83-B7D2-F7533020DA09
P2860
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inflammation as a therapeutic ...... uropean Society of Cardiology.
@en
Inflammation as a therapeutic ...... uropean Society of Cardiology.
@nl
type
label
Inflammation as a therapeutic ...... uropean Society of Cardiology.
@en
Inflammation as a therapeutic ...... uropean Society of Cardiology.
@nl
prefLabel
Inflammation as a therapeutic ...... uropean Society of Cardiology.
@en
Inflammation as a therapeutic ...... uropean Society of Cardiology.
@nl
P2093
P2860
P50
P356
P1476
Inflammation as a therapeutic ...... uropean Society of Cardiology.
@en
P2093
Blanche Schroen
Carsten Tschöpe
Heinz-Peter Schultheiss
Helmut Drexler
Jan W Cohen-Tervaert
Marc Van Bilsen
Roberto Latini
Stefan Janssens
Stephan B Felix
Stephane Heymans
P2860
P304
P356
10.1093/EURJHF/HFN043
P50
P577
2009-02-01T00:00:00Z